SELLAS Life Sciences Group (NASDAQ: SLS) experienced a notable uptick in its stock price on Friday, climbing 6.3% to $11.19, with an intraday high of $11.29. This rally outpaced the broader biotech sector, as the SPDR S&P Biotech ETF (XBI) gained 1.8%.
Heavy Short Interest and Trading Volume
The stock's movement was accompanied by a surge in trading activity. On Thursday, SLS saw volume of 15.11 million shares, nearly double its 65-day average of 7.57 million. Short interest remains elevated, with 63.36 million shares sold short as of June 15, representing 32.65% of the float. The days-to-cover ratio stood at 9.3, and at the current price, the short interest is valued at approximately $709 million.
Executive Severance Amendments
A Form 8-K filed on June 25 revealed changes to change-of-control severance terms for senior executives. CEO Angelos Stergiou is now entitled to a lump-sum severance payment, while CFO John Burns and Chief Development Officer Dragan Cicic have amended agreements. Under qualifying termination during a change-of-control, each executive would receive 15 months of base pay, target bonus, up to 18 months of COBRA reimbursement, and full vesting of unvested equity. The board approved these changes after consulting with an external compensation advisor.
Financial Position and Market Cap
SELLAS reported $107.1 million in cash as of March 31, with an additional $28.7 million from warrant proceeds in April and May. With 196.6 million shares outstanding, the market capitalization stands at approximately $2.20 billion, significantly exceeding the cash per share of about $0.69. This wide gap underscores the speculative nature of the trade, driven by the upcoming AML trial catalyst and a heavy short base.
Phase 3 AML Trial Update
The key catalyst is the REGAL trial, a Phase 3 study in acute myeloid leukemia. On May 12, the company reported that 78 of the 80 events required for final analysis had been reached as of May 11. CEO Angelos Stergiou stated, "The coming results will be an important milestone for the Company." Final analysis will commence after the 80th event.
Additional Pipeline Developments
SELLAS also initiated an 80-patient Phase 2 study of SLS009 in newly diagnosed AML, with topline data expected in the fourth quarter of 2026. This expands the company's pipeline beyond the REGAL trial.
Analyst Ratings and Market Implications
Despite the stock's rally, analyst targets remain subdued. FactSet data shows two buy ratings with an average price target of $10, below the current trading level. The combination of high short interest, a binary clinical catalyst, and a market cap far above cash makes SLS a high-risk, high-reward proposition for investors.
